Mobile Phone Cancer Link Looking Less And Less Likely
7/02/2011
Evidence from a growing number of studies does not support the theory that cellphones raise the risk of brain cancer, an independent international panel of experts has found after carrying out a thorough analysis of all published research. The analysis was carried out by the ICNIRP (International Commission on Non-Ionizing Radiation Protection) Standing Committee on Epidemiology...
Once-Daily Anticoagulant Xarelto Approved By FDA For DVT Prevention
7/02/2011
Blood thinner (anticoagulant) Xarelto (rivaroxaban tablets) has been approved by the FDA (Food and Drug Administration) for the prevention of DVT (deep vein thrombosis) in patients who had knee or hip replacement surgery. The tablets are taken once daily. According to Xarelto makers, Janssen Pharmaceuticals, Inc...
CT Scan Screening Reduces Lung Cancer Death Risk More Than X-rays
7/02/2011
Patients screened with low-dose helical CT (computed tomography) have a 20% lower risk of dying from lung cancer compared to those screened with chest X-rays, researchers reported in the New England Journal of Medicine (NEJM). The authors revealed their findings from NLST (National Lung Screening Trial), involving 53,000 individuals who either smoked heavily during the trial or used to do so...
"Triple-negative breast cancer (TNBC)", is one of the most life threatening forms of breast cancer. It is aggressive, least responsive to standard therapy and accounts for 10 to 20 percent of all breast cancers. In a recent breakthrough six distinct subtypes of this cancer have been recognized by scientists from the Vanderbilt-Ingram Cancer Center...
Targeting The Ewing Sarcoma Family Of Tumors
7/02/2011
The Max Cure Foundation and the Samuel Waxman Cancer Research Foundation have partnered to establish a fund in pediatric cancer research. With that goal in mind, the two Foundations are proud to announce the award of $100,000 to Erwin G. Van Meir, Ph.D., of Emory University School of Medicine in Atlanta...
ACORN Research Reports Positive Findings Of Phase 2b Metastatic Breast Cancer Trial At ASCO
7/02/2011
Accelerated Community Oncology Research Network, Inc., (ACORN), reported positive results of a large double-blind, randomized Phase 2b trial in patients with breast cancer at the American Society of Clinical Oncology (ASCO) 47th annual meeting in Chicago, June 3-7...
President Hugo Chavez Has Malignant Tumor Surgically Removed
7/01/2011
Venezuelan President Hugo Chavez announced on TV from Cuba that a malignant tumor was surgically removed from his "pelvic region". He says he is undergoing intensive post-operative medical therapy in Cuba and hopes to return to his country soon. Chavez explained to his nation that during his last trip he had planned to have his left knee checked by Cuban doctors...
GTx, Inc. (Nasdaq: GTXI) announced today that the effects of Ostarine™ (GTx-024) on physical function in patients with non-small cell lung cancer (NSCLC) will be the subject of an oral podium presentation at the 14th Annual World Conference on Lung Cancer, the annual meeting of the International Association for the Study of Lung Cancer being held July 3 - 7 in Amsterdam, The Netherlands...
Advaxis Granted Pre-IND Meeting With The FDA For Advaxis-PSA Prostate Immunotherapy
7/01/2011
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration ("FDA") on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer...
Scancell Develops New Vaccine For The Treatment Of Lung Cancer
7/01/2011
Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with Homspera®, an adjuvant developed by ImmuneRegen BioSciences, Inc.® has produced encouraging anti-tumour results in animal models...